Pulmonary thromboembolism remains one of the most severe vascular manifestations of antiphospholipid syndrome. Clinicians traditionally prescribe vitamin K antagonists like warfarin to prevent recurrent clot formation in these high-risk individuals. However, the routine use of DOACs in non-triple-positive APS has emerged as a topic of intense clinical debate. Contemporary research offers crucial real-world insights into whether direct oral anticoagulants can serve as a dependable alternative to conventional vitamin K antagonist therapy.

Clinical Dilemma: Anticoagulation in Antiphospholipid Syndrome

Antiphospholipid syndrome is an autoimmune condition defined by vascular thrombosis or obstetrical morbidity linked to persistent antiphospholipid antibodies. Historically, landmark randomized trials demonstrated that direct oral agents failed to match warfarin in high-risk patients who displayed triple antibody positivity. Consequently, major international guidelines strictly recommend against using factor Xa or direct thrombin inhibitors in triple-positive disease. Nevertheless, clinical hematologists frequently encounter lower-risk presentations. These include patients harboring single or double antibody positivity without prior arterial occlusive events. In daily clinical settings, maintaining therapeutic international normalized ratio levels with warfarin poses significant challenges. Frequent phlebotomy, extensive dietary interactions, and unpredictable fluctuations complicate long-term management. Therefore, healthcare providers actively investigate whether non-triple-positive patients can safely receive direct agents without elevating recurrence risks.

Study Design and Patient Selection Criteria

To evaluate this critical therapeutic question, investigators conducted a retrospective cohort analysis at the First Affiliated Hospital of Chongqing Medical University. The clinical team scrutinized records from July 2016 through July 2021. They enrolled consecutive adult patients with definitively diagnosed pulmonary thromboembolism fulfilling the Sapporo diagnostic classification for antiphospholipid syndrome. Importantly, the researchers excluded triple-positive profiles. They categorized the remaining eligible cohort based on their prescribed oral regimen. Ultimately, thirty-four patients received direct oral anticoagulants, while nine patients received warfarin. Baseline demographic variables, underlying autoimmune comorbidities, and laboratory parameters underwent systematic collection. The mean age was 57.0 years in the direct oral agent group and 37.7 years in the warfarin group. Aside from this statistically significant age discrepancy, both therapeutic cohorts displayed comparable baseline clinical characteristics.

Evaluating DOACs in Non-Triple-Positive APS for Thromboembolic Recurrence

The primary efficacy endpoint focused directly on recurrent venous thromboembolic events during longitudinal clinical follow-up. During the surveillance interval, secondary venous thrombosis developed in two patients within the direct oral anticoagulant cohort, representing a recurrence rate of 5.9 percent. In contrast, zero patients in the warfarin cohort suffered a documented recurrent clot. Statistical analysis confirmed that this difference was not statistically significant. Furthermore, neither group experienced all-cause mortality during the follow-up period. These clinical findings indicate that direct oral agents achieve therapeutic efficacy comparable to vitamin K antagonists in this lower-risk subset. Because the trial specifically evaluated patients with pulmonary embolism, the results provide valuable reassurances to pulmonologists and vascular medicine specialists. Thus, treatment failure rates appear modest when physicians restrict direct agents strictly to non-triple-positive presentations.

Safety Analysis: Anticoagulation-Related Bleeding Complications

Bleeding complications represent the foremost safety hazard in patients requiring indefinite anticoagulant therapy. In this study, safety assessments examined both major hemorrhages and clinically relevant non-major bleeding episodes. Investigators observed bleeding events in four patients receiving direct oral anticoagulants, yielding an overall incidence of 11.8 percent. Meanwhile, three patients in the warfarin group experienced bleeding episodes, translating to a substantially higher proportion of 33.3 percent. Statistical computation revealed a relative risk ratio of 0.353 with a 95 percent confidence interval spanning 0.096 to 1.301. Consequently, this numerical reduction in hemorrhagic events did not reach statistical significance. Nonetheless, the safety profile of direct agents proved acceptable. Direct oral anticoagulants did not cause excess bleeding events compared to carefully monitored warfarin therapy.

Clinical Implications for Practice and Risk Stratification

These findings provide pragmatic evidence for clinicians managing venous thromboembolism in the context of antiphospholipid antibodies. Strict antibody profiling remains paramount before initiating or continuing oral antithrombotic therapy. Specifically, clinicians must test for lupus anticoagulant, anti-cardiolipin antibodies, and anti-beta-2-glycoprotein I antibodies. If testing reveals triple positivity or prior arterial events, warfarin remains the indisputable standard of care. Conversely, for individuals possessing single or double positivity who struggle with international normalized ratio monitoring, direct oral anticoagulants offer a feasible therapeutic alternative. Clinicians must practice shared decision-making, discussing individual bleeding propensities, lifestyle considerations, and monitoring capabilities. While prospective randomized trials must validate these observations, retrospective data suggest that targeted patient selection permits effective anticoagulation without compromising clinical safety.

Can patients with single-positive antiphospholipid syndrome safely switch to DOACs?

Patients with single-positive antiphospholipid syndrome may consider switching to direct oral anticoagulants if they struggle with warfarin monitoring. Clinical studies suggest these individuals have lower recurrence risks than triple-positive patients. However, physicians must verify complete antibody panels, assess bleeding history, and ensure the absence of prior arterial thrombosis before executing any medication switch under strict clinical supervision.

Why are DOACs contraindicated in patients with triple-positive antiphospholipid syndrome?

Major randomized controlled trials demonstrated that direct oral anticoagulants cause a significantly higher rate of recurrent thromboembolism, particularly arterial strokes, compared to warfarin in triple-positive patients. Triple positivity conveys the highest thrombotic risk profile. Consequently, international guidelines strictly mandate therapeutic warfarin with target international normalized ratios between 2.0 and 3.0 for this vulnerable cohort.

What laboratory monitoring is required for patients with APS taking DOACs?

Direct oral anticoagulants do not require routine coagulation monitoring such as international normalized ratio testing. However, clinicians must regularly assess renal function, complete blood counts, and hepatic parameters to ensure appropriate drug clearance and identify occult bleeding. Furthermore, periodic re-evaluation of antiphospholipid antibody status is recommended to verify that patient risk profiles have not evolved.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Clinical decisions should be made by qualified healthcare professionals based on individual patient assessments and established clinical guidelines. Refer to the latest local and national guidelines for clinical practice.

References

Hu CC et al. [Efficacy and safety of direct oral anticoagulants for the treatment of non-triple-positive antiphospholipid syndrome-associated pulmonary thromboembolism]. Zhonghua Jie He He Hu Xi Za Zhi. 2026 Sep 12. doi: 10.3760/cma.j.cn112147-20251214-00789. PMID: 42706207.
Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304.
Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-1371.
Woller SC, Stevens SM, Kaplan D, et al. Apixaban compared with warfarin to prevent thrombosis in patients with antiphospholipid syndrome: a randomized trial. Blood. 2022;140(suppl 1):814-816.